Background: Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon.
Book Title: Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial
Author:
Published on 2017 by
ISBN: /
Total Page:
Book Category:
Book is About: Carcinoma
Download Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial eBook
Background: Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon. We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety and activity in patients with metastatic or surgically unresectable urothelial carcinoma whose disease progressed or recurred despite previous treatment with at least one platinum-based chemotherapy regimen. Methods: In this multicentre, phase 2, single-arm study, patients aged 18 years or older with metastatic or surgically unresectable locally advanced urothelial carcinoma, measurable disease (according to Response Evaluation Criteria In Solid Tumors v1.1), Eastern Cooperative Oncology Group performance statuses of 0 or 1, and available tumour samples for biomarker analysis received nivolumab 3 mg/kg intravenously every 2 weeks until disease progression and clinical deterioration, unacceptable toxicity, or other protocol-defined reasons. The primary endpoint was overall objective response confirmed by blinded independent review committee in all treated patients and by tumour PD-L1 expression (≥5% and ≥1%). This trial is registered withClinicalTrials.gov, numberNCT02387996, and is completed. Follow-up is still ongoing. Findings: Between March 9, 2015, and Oct 16, 2015, 270 patients from 63 sites in 11 countries received nivolumab, and 265 were evaluated for activity. Median follow-up for overall survival was 7·00 months (IQR 2·96–8·77). Confirmed objective response was achieved in 52 (19·6%, 95% CI 15·0–24·9) of 265 patients. Confirmed objective response was achieved in 23 (28·4%, 95% CI 18·9–39·5) of the 81 patients with PD-L1 expression of 5% or greater, 29 (23·8%, 95% CI 16·5–32·3) of the 122 patients with PD-L1 expression of 1% or greater, and 23 (16·1%, 95% CI 10·5–23·1) of the 143 patients with PD-L1 expression of less than 1%. Grade 3–4 treatment-related adverse events occurred in 48 (18%) of 270 patients—most commonly grade 3 fatigue and diarrhoea, which each occurred in five patients. Three deaths were attributed to treatment (pneumonitis, acute respiratory failure, and cardiovascular failure). Interpretation: Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and was associated with an acceptable safety profile in previously treated patients with metastatic or surgically unresectable urothelial carcinoma. Funding: Bristol-Myers Squibb.
Our website offers free Carcinoma Ebooks to download. Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial is the one of great book to have from us, a free ebooks portal, the best free ebooks download library. You can find and download free ebooks in categories. No registration is required to download free e-books. We have huge collection of Carcinoma and ebooks. Each downloadable ebook has a short review with a description. You can find over thousand of ebooks that are free to download. Get ton of books with us, the open directory for free ebooks and download links, the best place to read ebooks and search free download ebooks.Carcinoma ebooks free
download Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial ebook as PDF, EPUB, MOBI, AZW and AZW3, FB2, DJVU, LIT, RFT, IBA, LRS, LRF, and LRX.
download ebooks
There are so many ebooks about Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial that are available to have. Thinking of having Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial ebook? You are in the right place. Get the ebook Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial by: .
Book Details:
- Book was ranked at 33 by Google Books for Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial
- Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial published by since 2017 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=dXr1vQEACAAJ&dq=Carcinoma&hl=&cd=232&source=gbs_api
Book Preview
The Button is not working? Try The Alternative links for "Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): a Multicentre, Single-arm, Phase 2 Trial by: ":
- Server 2: SECURE LINK